Navigation Links
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
Date:11/5/2007

ured by PSA, and that patient remains on study lasting 9 cycles. Of the three patients in Arm 2 of the study, one progressed on treatment, one discontinued treatment prior to evaluation, and one patient had a confirmed partial response and remains on study after 7 cycles.

In summary, the first five evaluable patients there were two confirmed durable partial responses and one patient with stable disease. No grade 3 or 4 adverse events were reported to date and the two responding patients remain on trial. This study is currently actively enrolling.

Phase 2 Trial of TPI 287 for Pancreatic Cancer Initiated

Tapestry also initiated in the third quarter a second Phase 2 trial to explore the activity of TPI 287 in advanced pancreatic cancer. The trial is a multi-center, open-label, single arm Phase 2 study for up to 65 patients with advanced stage, unresectable pancreatic cancer, who have failed a prior gemcitabine-containing chemotherapy regimen for their disease. The trial will be conducted in approximately 10 to 15 centers in the U.S., Europe and India. This study is currently actively enrolling.

Data Presented from Preclinical Studies at International Cancer Conference

Tapestry also presented preclinical data on TPI-287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The poster presentation outlined the results of a number of different assays that confirm the Company's earlier observations that TPI 287 is less sensitive in a variety of resistant cancer cell lines to MDR1 mediated efflux than other approved taxanes. MDR1 mediated drug efflux may be a primary cause of resistance to chemotherapy with taxanes. Also presented was data showing that TPI 287 is retained at higher levels in MDR1 expressing cell lines than either paclitaxel or IDN 5109, another taxane in development purported to be active in MDR1 expressing tumors. In addition, data was presented that demonstrated tumor growth inhibition o
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear ... (Primary & Secondary), and End-User (Transmission & Distribution, ... Generation) - Trends and Forecasts to 2019”, defines ... forecasting of the market size. , Browse more ... spread through 146 Pages and in-depth TOC on ...
(Date:10/27/2014)... New Q4-2014 incentives help SoundConnect partners ... leading unified communication and collaboration provider, launches new ... cloud-based audio and web/video conferencing solutions to their ... Q4 incentive partners will earn $400.00 ... licenses sold, now through December 31st, 2014. , ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on the following ... Insmed Inc. (NASDAQ: INSM ), BioCryst Pharmaceuticals ... DYAX ), and Oncothyreon Inc. (NASDAQ: ONTY). ... at: http://investor-edge.com/register . On Friday, October ... 0.69%, the Dow Jones Industrial Average advanced 0.76%, to ...
(Date:10/25/2014)... (PRWEB) October 23, 2014 BioProcess ... winners for the 2014 BioProcess International Awards. The ... social corporate responsibility and technology applications that will ... treatments to a global patient base. , Winners ... peers during a very entertaining and exciting awards ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5
... Votes "FOR" Required for Integra Merger, IRVINE, California, ... an orthobiologics company, today announced that,it has adjourned the ... approve the acquisition of IsoTis by Integra LifeSciences Holdings,Corporation ... and plan of,merger dated as of August 6, 2007. ...
... 24 Immunosyn,Corporation,s (OTC Bulletin Board: IMYN) CEO, ... financial institutions at the Financial,Services Exchange (FSX) Investment ... AZ on Thursday, October 25, 2007. Immunosyn ... to SF-1019 from its largest shareholder, Argyll,Biotechnologies, LLC. ...
... Spine Centers Committed to the IEP,s Rollout in ... Magnifi Group, considered by,many industry observers to be ... medical device and pharmaceutical industries,announced here today at ... intent to organize and develop real-time Internet-based 3D,interactive ...
Cached Biology Technology:IsoTis Adjourns Special Meeting to October 26, 2007 2IsoTis Adjourns Special Meeting to October 26, 2007 3IsoTis Adjourns Special Meeting to October 26, 2007 4Immunosyn Corporation to Present at FSX 2Magnifi Group Demonstrates Industry's First Interactive Educational Program (IEP) for Spine Fellows 2
(Date:10/28/2014)... to expand the Office of Rare Diseases Research ... Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical Research Network ... 22 consortia will work with 98 patient advocacy ... treatments for patients with rare diseases. The collaborations ... 2014 funding from NIH. , Rett syndrome, MECP2 ...
(Date:10/28/2014)... Singapore (NTU Singapore) will be building a hybrid ... sources. , The first in the region, the ... of solar, wind, tidal-current, diesel, storage and power-to-gas ... together. , To be built under the new ... hybrid micro-grid will be located offshore at Semakau ...
(Date:10/27/2014)... Adélie penguins are an indigenous species of the West ... areas on Earth. Since 1950, the average annual temperature ... on average, and 6 degrees Celsius during winter. ... from a dry, polar system to a warmer, sub-polar ... recently reported a connection between local weather conditions and ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3University of Delaware study connects penguin chick weights to local weather conditions 2University of Delaware study connects penguin chick weights to local weather conditions 3
... expression of genes by turning them on or off at ... or cure of many diseases, say researchers at UT Southwestern ... of malfunctioning gene expression, or viral or bacterial gene expression," ... is an approach that could theoretically produce a drug for ...
... Vegetal of the Department of Agricultural Production at the ... for the best research in the area of viticulture. ... of Horticultural Science recently held in Oporto (Portugal). The ... grape varieties after a hydric stress event", studied the ...
... spent more than two decades leading efforts to combat ... relief supplies of antiretroviral therapies currently being distributed in ... those who can least afford to pay for them. ... of Public Health online June 28, infectious disease specialist ...
Cached Biology News:Gene silencing technique offers new strategy for treating, curing disease 2Best research work in the area of wine growing 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 3Hopkins AIDS experts issue warning about global efforts to provide drug therapies 4
... 3-D Shaker , ,Product Information ... the GyroTwister GX-1000 is extremely efficient, yet ... mixing as well as staining gels, hybridization ... adjustable across a broad range. A nonslip ...
... Scientific ChromQuest Chromatography Data System (CDS) ... data acquisition, chromatography data processing and ... High Speed LC. The companys innovative ... maximize the benefits of Thermo Scientific ...
... robotic system and disposable ESI Chip allow ... capabilities of electrospray mass spectrometers for life ... allows users to either speed analysis for ... mapping applications, or long acquisition times for ...
... coli Biotinylation Kit, Linear Template is designed for ... kits. (Cat. No. 3 186 148, 3 186 ... linear expression constructs by PCR containing and optimized ... of T7 RNA polymerase and prokaryotic cell lysate. ...
Biology Products: